# AORTA Gene: Polygenic prediction improves detection of thoracic aortic aneurysm

James P. Pirruccello MD<sup>1,2,3</sup>, Shaan Khurshid MD, MPH<sup>4,5,6,7</sup>, Honghuang Lin PhD<sup>8,9</sup>,
 Lu-Chen Weng PhD<sup>5,6</sup>, Siavash Zamirpour MS<sup>10</sup>, Shinwan Kany MD<sup>6,11</sup>, Avanthi
 Raghavan MD<sup>4,6</sup>, Satoshi Koyama MD, PhD<sup>5,6,12</sup>, Ramachandran S. Vasan MD<sup>8,13,14</sup>,
 Emelia J. Benjamin MD, ScM<sup>8,13,14</sup>, Mark E. Lindsay MD, PhD<sup>4,5,6,7,15</sup>, Patrick T. Ellinor
 MD, PhD<sup>4,5,6,7</sup>

1 Division of Cardiology, University of California San Francisco, San Francisco, California, USA, 2 Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA, 3 Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA, 4 Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA, 5 Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA, 6 Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, 7 Harvard Medical School, Boston, Massachusetts, USA, 8 Framingham Heart Study, Boston University and National Heart, Lung, and Blood Institute, Framingham, Massachusetts, USA, 9 Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA, 10 School of Medicine, University of California San Francisco, San Francisco, California, USA, 11 Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Hamburg, Germany, 12 Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan, 13 Department of Medicine, Cardiology and Preventive Medicine Sections, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA, 14 Epidemiology Department, Boston University School of Public Health, Boston, Massachusetts, USA, 15

Running Title: AORTA Gene

Word Count: 4,053

1

2

3 4

10 11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29 30

31

32

33

34 35 **Keywords**: Ascending aorta, polygenic score, UK Biobank, All of Us, Framingham

Thoracic Aortic Center, Massachusetts General Hospital, Boston, Massachusetts, USA

Heart Study, Mass General Brigham

#### Correspondence:

36 James P. Pirruccello, MD Patrick T. Ellinor, MD, PhD

37 University of California San Francisco Massachusetts General Hospita

38 Division of Cardiology

39 555 Mission Bay Blvd South #3118

40 San Francisco, CA 94158

41 james.pirruccello@ucsf.edu

Massachusetts General Hospital
Cardiology Division
55 Fruit Street
Boston, MA 02114
ellinor@mgh.harvard.edu

**Abstract** 

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Background: Thoracic aortic disease is an important cause of morbidity and mortality in the US, and aortic diameter is a heritable contributor to risk. Could a polygenic prediction of ascending aortic diameter improve detection of aortic aneurysm? Methods: Deep learning was used to measure ascending thoracic aortic diameter in 49,939 UK Biobank participants. A genome-wide association study (GWAS) was conducted in 39,524 participants and leveraged to build a 1.1 million-variant polygenic score with PRScs-auto. Aortic diameter prediction models were built with the polygenic score ("AORTA Gene") and without it. The models were tested in a held-out set of 4,962 UK Biobank participants and externally validated in 5,469 participants from Mass General Brigham Biobank (MGB), 1,298 from the Framingham Heart Study (FHS), and 610 participants from *All of Us*. Results: In each test set, the AORTA Gene model explained more of the variance in thoracic aortic diameter compared to clinical factors alone: 39.9% (95% CI 37.8-42.0%) vs 29.2% (95% CI 27.1-31.4%) in UK Biobank, 36.5% (95% CI 34.4-38.5%) vs 32.5% (95% CI 30.4-34.5%) in MGB, 41.8% (95% CI 37.7-45.9%) vs 33.0% (95% CI 28.9-37.2%) in FHS, and 34.9% (95% CI 28.8-41.0%) vs 28.9% (95% CI 22.9-35.0%) in All of Us. AORTA Gene had a greater AUROC for identifying diameter ≥4cm in each test set: 0.834 vs 0.765 (P=7.3E-10) in UK Biobank, 0.808 vs 0.767 in MGB (P=4.5E-12), 0.856 vs 0.818 in FHS (P=8.5E-05), and 0.827 vs 0.791 (P=7.8E-03) in All of Us.

**Conclusions**: Genetic information improved estimation of thoracic aortic diameter when added to clinical risk factors. Larger and more diverse cohorts will be needed to develop more powerful and equitable scores.

65

66

67

68

# Introduction

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

Thoracic aortic disease is an important cause of morbidity and mortality<sup>1,2</sup>. Ascending thoracic aortic enlargement is a well-established risk factor for ascending aortic dissection<sup>3,4</sup>. Indeed, the majority of dissections occur in individuals with a ortic diameter ≥4cm, including more than 90% in the International Registry of Aortic Dissection and 100% in Kaiser<sup>4,5</sup>. Contemporary guidelines do not describe a role for population screening of thoracic aortic aneurysm<sup>6</sup>, and universal imaging would likely be impractical. These limitations have spurred the development of clinical risk scores to identify individuals who are likely to have a rtic enlargement on confirmatory imaging 7-9. These scores have been shown to explain approximately 30% of the variance in ascending aortic diameter, with an area under the receiver operator characteristic curve (AUROC) near 0.78 for detecting individuals with diameter ≥4cm. Population genetics studies suggest that ascending aortic diameter is highly heritable, with a proportion of variance attributable to common genetic factors of over 60% 10. We therefore sought to assess whether incorporating polygenic risk might improve estimation of ascending aortic diameter over clinical factors alone.

# Methods

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

5/35

Study design Model development and internal validation were conducted in UK Biobank, with external validation within the All of Us cohort, the Mass General Brigham Biobank (MGB), and the Framingham Heart Study (FHS). This study was reported in accordance with the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement<sup>11</sup>. Study protocols complied with the tenets of the Declaration of Helsinki. All UK Biobank participants provided written informed consent<sup>12</sup>, and only those participants who had not withdrawn consent as of March 7, 2023 were analyzed. The UK Biobank analyses were considered exempt by the UCSF Institutional Review Board (IRB), #22-37715. UK Biobank analyses were conducted under application #41664. Each All of Us biobank participant provided written informed consent<sup>13</sup>. The All of Us analyses were considered exempt by the UCSF IRB, #22-37715. The MGB study protocols were approved with a waiver of informed consent by the Mass General Brigham IRB. All FHS participants provided written informed consent, and the FHS imaging analyses were previously approved by the IRB of the Boston University Medical Center<sup>14</sup>. The FHS analyses were also approved by the MGB IRB. Study populations In UK Biobank participants, ascending aortic diameter was measured from magnetic resonance imaging (MRI) using a previously described deep learning model<sup>15</sup>. Model

**AORTA Gene** 

development and internal validation were conducted in UK Biobank. External validation of the models was pursued in MGB participants with ascending aortic diameter measured from TTE for clinical indications<sup>16</sup>; in FHS participants with ascending aortic diameter measured for research purposes from non-contrast computed tomography (CT)<sup>14</sup>; and in *All of Us* biobank participants who had clinical aortic diameter measurements from transthoracic echocardiography (TTE)<sup>13</sup>. In MGB, race or ethnicity was extracted from the electronic health record<sup>16</sup> and the validation analyses were repeated in individuals identified as Black.

### **Modality-specific differences**

The clinical approach to measuring ascending aortic diameter differs by modality. UK Biobank MRI-based aortic diameter measurements were derived from the blood pool diameter only, incorporating neither aortic wall. For TTE, used in the MGB and *All of Us* cohorts, standard measurements use the "leading edge to leading edge" approach, incorporating one wall. For non-contrast CT measurements, used in FHS, both walls are incorporated into the diameter.

# Splitting the UK Biobank for training and validation

49,939 UK Biobank participants with MRI measurements of aortic diameter were randomly assigned a number from 0-999. Those from 0-799 contributed to the genome-wide association study (GWAS) used to produce the polygenic score (N=39,524). Those from 800-999 related within 3 degrees of kinship to the 0-799 group were excluded to avoid polygenic score overfitting (N=557). Those remaining from 0-899 contributed to the development of non-genetic models (N=44,420). Those from 800-899 were included

in the derivation of weights for the polygenic score component of the AORTA Gene combined clinical and genetic model (N=4,896). Those ≥900 were analyzed for validation (N=4,962; Figure 1). Thoracic aortic aneurysm in *All of Us* Within All of Us, thoracic aortic aneurysm was defined as the first occurrence of SNOMED codes 433068007, 74883004, or 426948001; ICD10CM codes of I71.01, 171.1, 171.2, or 177.810; ICD9CM codes of 441.01, 441.1, 441.2, or 447.71; ICD10PCS codes of 02RX0JZ or 02RW0JZ; the ICD9Proc code 39.73; or CPT4 codes 33863, 75957, 33880, 75956, or 33881. Prevalent analyses were conducted based on the presence of disease labels prior to the time of enrollment. Time-to-event analyses were conducted beginning at the time of enrollment and censored on July 1, 2022 using the R survival package, excluding participants whose diagnoses occurred prior to enrollment. Any tabular data with an All of Us sample count <20 was modified in accordance with All of Us policies. Genome-wide association study and polygenic scores Common genetic contributions to ascending aortic diameter in the 39,524 GWAS participants were discovered using REGENIE v3.2.7<sup>17</sup> with imputed variants provided by UK Biobank<sup>18,19</sup>. GWAS covariates included age, age<sup>2</sup>, sex, the MRI serial number, the genotyping array, and the first ten principal components of ancestry. The summary statistics were trimmed to the ~1.1 million UK Biobank-specific variants within HapMap3 identified by the PRScs authors, and underwent Bayesian weighting by PRScs-auto on its default settings to produce polygenic score weights<sup>20</sup>.

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

The polygenic score was applied to all UK Biobank participants with imputed genetic data<sup>19</sup>. Variants with imputation quality <0.3 were removed. The polygenic score was applied to all MGB participants with imputed genetic data 16,21 with imputation into the TOPMed panel<sup>22</sup>. The polygenic score was applied to FHS participants with CT and genetic data available. For FHS, genotyping was done on the Affymetrix GeneChip 500K Array Set & 50K Human Gene Focused Panel (Affymetrix, Santa Clara, CA, USA). Variants with call rate <97% or Hardy-Weinberg equilibrium P<1E-06 were excluded. The remaining variants were then imputed to the 1000 Genomes Project phase I release 3 panel by MACH version 1.0<sup>23,24</sup>. Variants with imputation quality <0.3 were removed. The polygenic score was applied to All of Us participants with whole genome sequencing data available in release "R7"<sup>25</sup>. Within each set of participants, the polygenic score was residualized for the first 20 principal components of ancestry (except for FHS, where 10 were used due to availability). The polygenic score in each group was zero-centered and scaled by the standard deviation from the UK Biobank training set: for studies that applied the average polygenic score (UK Biobank, All of Us) the standard deviation was 3.4E-07,

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

and for those that applied the summed polygenic score (MGB, FHS) the standard deviation was 0.38.

#### Ascending aortic diameter model training

Hierarchical group least absolute shrinkage and selection operator models were built to estimate ascending aortic diameter using the R package *glinternet*<sup>26</sup>. Three models were constructed with *glinternet* v1.0.11 using the following independent variables: (a) age, age<sup>2</sup>, and sex; (b) age, age<sup>2</sup>, sex, and polygenic score; (c) age, age<sup>2</sup>, body mass index (BMI), heart rate, systolic and diastolic blood pressure, height, weight, sex, and a history of diabetes, hypertension, or hyperlipidemia. A fourth model (d) was constructed by taking a linear combination of the model (c) and the polygenic score. The weighting for model (c) was estimated in all participants randomly assigned to 0-899, while the weighting for model (b) and the linear combination for model (d) were estimated in those assigned to 800-899 to avoid overlap with the GWAS cohort. For ease of reference, we label model (c) "AORTA Score" (AORTA: optimized regression for thoracic aneurysm) and model (d) "AORTA Gene".

# Statistical analysis

9/35

All statistical significance tests were two-sided, with significance defined as P < 0.05, and performed in R 4.2.3 unless otherwise stated. For visualization, scores were plotted against measured thoracic aortic diameter.

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Outcomes The primary outcome was correlation between the scores and ascending aortic diameter using linear models, expressed as R<sup>2</sup> (variance explained). Secondary outcomes included tests of calibration, and the performance of the scores for identifying ascending aortic diameter ≥4.0cm; the clinical diagnosis of aneurysm was also tested in All of Us. To assess calibration, each score was used as an independent variable in a linear model predicting aortic diameter that also had an intercept, permitting significance testing of both the slope and the intercept. Mean absolute error was also computed. To assess the performance for identifying diameter ≥4cm, the AUROC was computed. Confusion matrices and their derived statistical measures were produced based on the presence or absence of aortic diameter ≥4cm and the presence or absence of predicted diameters above a fixed threshold determined in the training set for each score. The thresholds for the confusion matrix analysis were defined in the 4,896 participants in the training set. AUROCs were compared using the DeLong test<sup>27</sup>. The continuous net reclassification index (NRI) was calculated following the formula of Pencina, et  $al^{28}$ . Data and code availability Computed scores are returned to UK Biobank, where data are made available by UK Biobank to researchers from research institutions with genuine research inquiries, 10/35 AORTA Gene

following IRB and UK Biobank approval. FHS data are made available to researchers with approved research applications. The dbGAP study accession number used for FHS validation was #phv00076329.v1.p5 for ascending aortic diameter. MGB data are available to MGB investigators; external collaboration requests can be initiated through https://biobank.massgeneralbrigham.org/for-researchers. The complete set of AORTA Score covariates and their weights are available as R programs at github.com/carbocation/genomisc and the polygenic score weights will be available on the Polygenic Score Catalog ( pgscatalog.org ).

# Results

Clinical characteristics

Among the 4,896 UK Biobank participants whose data contributed to training the genetic models, 2,489 were women and 2,407 were men. The ascending aortic diameter was 3.05 ± 0.31cm for women and 3.34 ± 0.34cm for men. The 4,962 internal validation set participants had similar measurements (**Table 1**; **Figure 1**). The MGB validation set consisted of 5,469 participants with genetic data and aortic diameter measured from TTE. The FHS validation set consisted of 1,298 participants with genetic data and aortic diameter measured from non-contrast CT. The *All of Us* validation set consisted of 610 participants 40 years and older with genetic data and aortic diameter measured from TTE; 60% identified as female and 88% as having non-Hispanic white ethnicity.

#### Model validation for aortic diameter

Testing calibration, the slope of the AORTA Gene model was statistically consistent with one in UK Biobank (P=0.2), MGB (P=1.0), FHS (P=0.6), and *All of Us* (P=0.4) (**Figure 2**). The intercept was consistent with zero in UK Biobank (P=0.2), MGB (P=0.4), and *All of Us* (P=0.8), but not FHS (intercept estimate 0.26cm, P=0.01). The same pattern was observed for the clinical AORTA Score. In contrast, the model incorporating only age, sex, and the polygenic score had a calibration slope inconsistent with one in most cohorts outside of UK Biobank (**eTable AA**).

The AORTA Gene model's mean absolute error (MAE) for ascending aortic diameter was 0.212cm (95% CI 0.207-0.217cm) in UK Biobank, 0.282cm (95% CI 0.275-0.289cm) in MGB, 0.344cm (95% CI 0.331-0.358cm) in FHS, and 0.293cm (95% CI 0.273-0.313cm) in All of Us. The clinical AORTA Score had an inferior MAE in all cohorts: 0.232cm (95% CI 0.227-0.237cm) in UK Biobank, 0.291cm (95% CI 0.284-0.298cm) in MGB, 0.351cm (95% CI 0.337-0.365cm) in FHS, and 0.306cm (95% CI 0.285-0.327cm) in All of Us. The age/sex/genetics model had an MAE of 0.226cm (95% CI 0.221-0.231cm) in UK Biobank, 0.293cm (95% CI 0.286-0.300cm) in MGB, 0.346cm (95% CI 0.332-0.360cm) in FHS, and 0.318cm (95% CI 0.296-0.340) in All of Us. The AORTA Gene model explained 39.9% of the variance in ascending aortic diameter (99% CI 37.8-42.0%; P=2.6E-551) in the UK Biobank validation set, 36.5% (95% CI 34.4-38.5%, P=2.4E-541) in MGB, 41.8% (95% CI 37.7-45.9%; P=3.5E-154) in FHS, and 34.9% (95% CI 28.8-41.0%; P=1E-58) in All of Us (Figure 3). In comparison, the clinical AORTA Score explained 29.3% of the variance in UK Biobank (99% CI 27.1-31.4%), 32.5% in MGB (95% CI 30.4-34.5%), 33.0% (95% CI 28.9-37.2%) in FHS, and 28.9% (95% CI 22.9-35.0%) in All of Us. The age/sex/genetics model explained 31.8% (95% CI 29.6-33.9%) of variance in UK Biobank, 33.2% (95% CI 31.2-35.3%) in MGB, 33.3% (95% CI 29.1-37.5%) in FHS, and 31.0% (95% CI 24.9-37.1%) in All of Us.

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

Model validation for a 4cm aortic diameter threshold 113 of the 4.962 internal validation set participants in UK Biobank had aortic diameter ≥4cm (2.3%), as did 335 of 5.469 MGB participants (6.1%), 116 of 1,298 FHS participants (8.9%), and 65 of 610 All of Us participants (10.7%). The AUROC for detecting diameter ≥4cm for the AORTA Gene model was 0.834 (95% CI 0.798-0.869) in UK Biobank, 0.808 (95% CI 0.783-0.832) in MGB, 0.856 (95% CI 0.821-0.891) in FHS, and 0.827 (95% CI 0.776-0.878) in All of Us (Figure 4: eTable BB). For the clinical AORTA Score, the AUROC was 0.765 (95% CI 0.723-0.807) in UK Biobank, 0.767 (95% CI 0.741-0.792) in MGB, 0.818 (95% CI 0.776-0.859) in FHS, and 0.791 (95% CI 0.735-0.846) for All of Us. The AUROC of AORTA Gene was significantly greater in all cohorts: P=7.3E-10 against a null hypothesis of no difference in UK Biobank, P=4.5E-12 in MGB, P=8.5E-05 in FHS, and P=7.8E-03 in All of Us (eTable CC). The age/sex/genetics model had an AUROC of 0.805 (95% CI 0.767-0.843) in UK Biobank, 0.805 (95% CI 0.781-0.829) in MGB, 0.819 (95% CI 0.781-0.856) in FHS, and 0.813 (95% CI 0.757-0.870) in All of Us. The AORTA Gene AUROC was significantly greater in UK Biobank (P=0.03) and FHS (P=3.9E-03), but not in MGB (P=0.7) or All of  $U_{\rm S}$  (P=0.5) (eTable CC).

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

The continuous NRI was positive for AORTA Gene over the clinical AORTA Score and the age/sex/genetics model in all cohorts (eTable CC). Decomposed into its NRI(event) and NRI(nonevent) components, AORTA Gene had a greater NRI(event) in all cohorts compared to the AORTA Score and the age/sex/genetics model. However, its NRI(nonevent) value was lower than that of the AORTA Score in MGB and UK Biobank, and lower than that of the age/sex/genetics model in MGB and All of Us.

#### Score threshold demonstrations

To evaluate the consequences of various score thresholds whereby a portion of the population could be brought forward for confirmatory thoracic imaging, two thresholds were defined within the UK Biobank training set and applied in the validation sets: one targeted at the top 10% of the population, and the other designed to have a sensitivity of 90% for aortic diameter ≥4cm (eTable BB).

For the target top 10% AORTA Gene cutoff, 485 (9.8%) of 4,962 participants were above this threshold in UK Biobank, 640 (11.7%) of 5,469 in MGB, 99 (7.6%) of 1,295 in FHS, and 97 (15.9%) of 610 in *All of Us.* 59 of 113 UK Biobank participants with diameter ≥4cm were correctly classified as enlarged (sensitivity 52.2%), as were 162 of 335 in MGB (48.4%), 47 of 116 in FHS (40.5%), and 35 of 65 in *All of Us* (53.8%). The precision was 0.122 in UK Biobank, 0.253 in MGB, 0.475 in FHS, and 0.361 in *All of Us*, yielding respective F1 scores of 0.197, 0.332, 0.437, and 0.432 (**eTable BB**). A comparable threshold for the clinical AORTA Score flagged 484 (9.8%) of 4,962 UK Biobank participants, 722 (13.2%) of 5,469 in MGB, 92 (7.1%) of 1,295 in FHS, and 110 (18.0%) of 610 in *All of Us.* 41 of 113 UK Biobank participants with diameter ≥4cm were 15/35

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

correctly classified as enlarged (sensitivity 36.3%) as were 143 of 335 in MGB (42.7%), 38 of 116 in FHS (32.8%), and 33 of 65 in All of Us (50.8%). The precision was 0.85 in UK Biobank, 0.198 in MGB, 0.413 in FHS, and 0.300 in All of Us, yielding respective F1 scores of 0.137, 0.271, 0.365, and 0.377 (eTable BB). For the target 90% sensitive AORTA Gene cutoff, 1,737 (35.0%) of 4,962 UK Biobank participants were above this threshold, 1,943 (35.5%) of 5,469 in MGB, 336 (25.9%) of 1,295 in FHS, and 247 (40.5%) of 610 in All of Us. 92 of 113 UK Biobank participants with diameter ≥4cm were correctly classified as enlarged (sensitivity 81.4%), as were 258 of 335 in MGB (77.0%), 88 of 116 in FHS (75.9%), and 56 of 65 in All of Us (86.2%). The precision was 0.053 in UK Biobank, 0.133 in MGB, 0.262 in FHS, and 0.227 in All of Us, yielding respective F1 scores of 0.099, 0.227, 0.389, and 0.359 (eTable DD). A comparable threshold for the clinical AORTA Score flagged 2,006 (40.4%) of 4,962 UK Biobank participants, 2,194 (40.1%) of 5,469 in MGB, 405 (31.3%) of 1,295 in FHS, and 266 (43.6%) of 610 in All of Us. 87 of 113 UK Biobank participants with diameter ≥4cm were correctly classified as enlarged (sensitivity 77.0%), as were 264 of 335 in MGB (78.8%), 86 of 116 in FHS (74.1%), and 52 of 65 in All of Us (80.0%). The precision was 0.043 in UK Biobank, 0.120 in MGB, 0.212 in FHS, and 0.195 in All of Us, yielding respective F1 scores of 0.082, 0.209, 0.330, and 0.314 (eTable DD). Thoracic aortic aneurysm diagnosis in *All of Us* In the 164,789 All of Us participants aged 40 or older with genetic data, 1,904 had an electronic health record (EHR)-based diagnosis of thoracic aortic aneurysm prior to 16/35 AORTA Gene

enrollment. AORTA Gene's AUROC was 0.760 (95% CI 0.750-0.771) compared to 0.739 (95% CI 0.728-0.750) for the AORTA Score (eTable EE), P=2.4E-16 against a null hypothesis of no difference (eTable FF). For incident disease (1,632 cases diagnosed after enrollment), AORTA Gene's AUROC was 0.748 (95% CI 0.737-0.759) compared to 0.729 (95% CI 0.718-0.741) for the AORTA Score, P=9.5E-10 against a null hypothesis of no difference (eTables EE-FF). Analysis in Black individuals in MGB In MGB, 340 individuals were identified as Black through the electronic health record 16. In these individuals, AORTA Gene had an intercept consistent with zero (P=0.5) and a slope consistent with one (P=0.5). The MAE was 0.297cm (95% CI 0.272-0.321cm). and the model explained 34.8% of variance in ascending aortic diameter (95% CI 26.7-43.0%). In comparison, for the clinical AORTA Score these values were 0.294cm (95% CI 0.269-0.319cm) and 34.3% (95% CI 26.2-42.5%) (eTable AA). The AUROC for detecting diameter ≥4cm for the AORTA Gene model was 0.858 (eTable BB), nominally greater than that of the clinical AORTA Score (AUROC 0.820, P=0.04 for the difference, **eTable CC**), with a positive continuous NRI (0.473).

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

# Discussion

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

Ascending thoracic aortic diameter has a SNP heritability estimated to be greater than 60%<sup>10</sup>, which makes the incorporation of common-variant genetic data for the presymptomatic detection of individuals with aortic enlargement or aneurysm conceptually appealing. But whether aortic polygenic scores encode information not already latently captured through correlation with clinical covariates was unknown. Here, we observed that AORTA Gene, which incorporated both an aortic polygenic score and clinical covariates, improved estimation of ascending aortic diameter and identification of individuals with diameter ≥4cm in four cohorts—UK Biobank, MGB, FHS, and All of Us—when compared to a previously validated model for a ortic diameter built from the same clinical covariates. For the estimation of aortic diameter as a quantitative measure, a clinical model built from the same covariates as the AORTA Score<sup>9</sup> explained 29.3% of the variance in ascending aortic diameter in UK Biobank, 28.9% in All of Us, 32.5% in MGB, and 33.0% in FHS. The AORTA Gene model that additionally incorporated the aortic diameter polygenic score increased those values to 39.9% in UK Biobank, 34.9% in All of Us, 36.5% in MGB, and 41.8% in FHS. These represent a 10.6% absolute improvement in explained variance (36% relative improvement) in UK Biobank, 4% (12.3% relative improvement) in MGB, 8.8% (27% relative improvement) in FHS, and 6% (21% relative improvement) in All of Us. These substantive improvements from the polygenic score over a clinical model are comparable in magnitude to the addition of key clinical predictors over age and sex alone<sup>9</sup>.

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

Incorporation of the polygenic score also improved identification of individuals with clinically relevant aortic enlargement (i.e., diameter ≥4cm). The clinical model had an AUROC of 0.765 in UK Biobank, 0.791 in All of Us, 0.767 in MGB, and 0.818 in FHS; these respectively improved to 0.834, 0.827, 0.808, and 0.856 for AORTA Gene. The AUROC is independent of the choice of score threshold, so we also demonstrated two example thresholds: one based on the goal of being 90% sensitive for diameter ≥4cm, and another based on a scenario where there are resources to image up to 10% of the population. In both scenarios, for all four cohorts, sensitivity and specificity were modestly improved with the incorporation of the polygenic score. Interestingly, we also observed that, compared to the comprehensive clinical score, a simpler model consisting only of age, sex, and the polygenic score performed similarly. Because such a model can be estimated for any future time from birth, this may have implications for attempts at early risk stratification before the onset of clinical risk factors. We also noted that, for the task of identifying All of Us participants with an EHR-based diagnosis of aneurysm, all models had attenuated performance—likely in part due to limited ascertainment of thoracic aortic disease in current clinical practice. Nevertheless, even for this task, the AORTA Gene model remained superior to the clinical score (P=9.5E-10). We also note two limitations of the current model that point to future directions: first, despite a heritability of nearly 60%, the current polygenic score for thoracic aortic diameter derived from a GWAS of 39,524 participants added approximately 10% to the

variance already explained by a clinical model, suggesting that it accounted for approximately 17% of the heritability of aortic diameter. In contrast, polygenic scores for height—built from GWAS of millions of participants—are nearly saturated<sup>29</sup>. Larger GWAS sample sizes are required to increase the variance explained by polygenic estimates of ascending aortic diameter. Second, polygenic scores derived in largely European-ancestry populations do not capture the full range of human genetic diversity, limiting their utility in individuals with more diverse genetic identities<sup>30</sup>. To examine this, we evaluated 340 individuals in MGB identified as Black in the electronic health record<sup>16</sup>. In these individuals, the addition of the polygenic score did not improve the continuous estimation of aortic diameter compared to the clinical score (R2 34.8% for AORTA Gene vs 34.3% for the clinical AORTA Score), although it did nominally improve identification of individuals with diameter ≥4cm (AUROC 0.858 vs 0.820. P=0.04). We expect a key problem from incorporating genetic data to be one of inequity due to differential accrual of benefits to individuals with European genetic identities. Larger and more diverse GWAS are required to improve genetic predictions for people across diverse genetic ancestries. Anticipation of the relevant clinical scenario for the application of polygenic scores is important for placing the current findings into context. The cost of acquiring a targeted set of images of the ascending thoracic aorta may be comparable that of obtaining genetic information. Therefore, we expect that the value of polygenic scores for primary prevention will be realized within the context of a healthcare system that incorporates genetic information as part of the prior probability across many diseases and risk

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

factors, where the cost of one-time genotyping would be amortized over all downstream uses. In such a system, might there be a role, in principle, for the incorporation of a genetic estimator of thoracic aortic diameter into a comprehensive model to identify people who are likely to have ascending aortic enlargement? The results from the present analysis suggest so.

#### Limitations

While all participants were incorporated into analyses without exclusion for race, ethnicity, or ancestry, the participants in UK Biobank, MGB, FHS, and *All of Us* with thoracic imaging predominantly had genetic identities similar to that of Europeans. None of the models described in this manuscript are anticipated to be effective for identifying individuals with aortic enlargement driven by rare pathogenic variants, which are not captured in polygenic scores constructed from common variants. The models were derived and tested in individuals over the age of 40 years. The attenuation in variance explained in the external cohorts compared to UK Biobank may be, in part, a consequence of cryptic relatedness causing overfitting to the UK Biobank cohort; reducing this discrepancy is an area of interest for future efforts. Future efforts are also needed to understand whether aortic prediction models can improve outcomes.

#### Conclusion

Integrating genetic information into a validated clinical model improved estimation of ascending aortic diameter and the identification of individuals with thoracic aortic aneurysm.

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

22/35

Acknowledgments JPP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. JPP and PTE conceived of the study. JPP conducted the genetic analyses, developed the models, validated the models, and conducted bioinformatic analyses in the UK Biobank, MGB, and All of Us. HL validated the models in FHS. LCW applied the polygenic score in MGB. S Koyama performed PCA in MGB. JPP and PTE wrote the paper. All other authors contributed to the analysis plan or provided critical revisions. Sources of funding Organizations that provided financial support had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation. review, or approval of the manuscript; or decision to submit the manuscript for publication. Dr. Pirruccello is supported by National Institutes of Health (NIH) K08HL159346. Dr. Lin is supported by the NIH grant U01AG068221. Dr. Kany is supported by the Walter-Benjamin Fellowship from the Deutsche Forschungsgemeinschaft (521832260). Dr. Raghavan is supported by the John S. LaDue Memorial Fellowship in Cardiovascular Medicine from Harvard Medical School. Dr. Benjamin is supported by NIH grants R01HL128914, R01HL092577, R01HL141434, and U54HL120163; and American Heart Association (AHA) grant 18SFRN34110082. Dr. Lindsay is supported by the Fredman

AORTA Gene

Fellowship for Aortic Disease and the Toomey Fund for Aortic Dissection Research and

has received salary support from Bayer AG. Dr. Ellinor is supported by grants from the NIH (R01HL092577, 1R01HL157635), from the AHA Strategically Focused Research Networks (18SFRN34110082), and from the European Union (MAESTRIA 965286). The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants. From the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine, this project has been funded in whole or in part with Federal funds from the National Heart Lung and Blood Institute, Department of Health and Human Services, under Contract No. 75N92019D00031.

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

# Disclosures

487

488

489

490

491

492

Dr. Ellinor has received sponsored research support from Bayer AG, IBM Health, Bristol Myers Squibb and Pfizer. Dr. Ellinor has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. The Broad Institute has filed for a patent on an invention from Drs. Ellinor, Lindsay, and Pirruccello related to a previous genetic risk predictor for aortic disease. Remaining authors report no disclosures.

# References

- Howard DPJ, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM, Oxford
   Vascular Study. Population-based study of incidence and outcome of acute aortic
   dissection and premorbid risk factor control: 10-year results from the Oxford
   Vascular Study. *Circulation*. 2013;127:2031–2037.
- Yamaguchi T, Nakai M, Yano T, Matsuyama M, Yoshino H, Miyamoto Y, Sumita Y,
   Matsuda H, Inoue Y, Okita Y, Minatoya K, Ueda Y, Ogino H. Population-based
   incidence and outcomes of acute aortic dissection in Japan. *European Heart* Journal Acute Cardiovascular Care. 2021;10:701–709.
- 502 3. Kim JB, Spotnitz M, Lindsay ME, MacGillivray TE, Isselbacher EM, Sundt TM. Risk 503 of Aortic Dissection in the Moderately Dilated Ascending Aorta. *J Am Coll Cardiol*. 504 2016;68:1209–1219.
- 505 4. Solomon MD, Leong T, Sung SH, Lee C, Allen JG, Huh J, LaPunzina P, Lee H, 506 Mason D, Melikian V, Pellegrini D, Scoville D, Sheikh AY, Mendoza D, Naderi S, 507 Sheridan A, Hu X, Cirimele W, Gisslow A, Leung S, Padilla K, Bloom M, Chung J, 508 Topic A, Vafaei P, Chang R, Miller DC, Liang DH, Go AS, Kaiser Permanente 509 Northern California Center for Thoracic Aortic Disease. Association of Thoracic 510 Aortic Aneurysm Size With Long-term Patient Outcomes: The KP-TAA Study. 511 JAMA Cardiology [Internet]. 2022 [cited 2022 Oct 11]; Available from: 512 https://doi.org/10.1001/jamacardio.2022.3305
- 5. Pape LA, Tsai TT, Isselbacher EM, Oh JK, O'gara PT, Evangelista A, Fattori R, Meinhardt G, Trimarchi S, Bossone E, Suzuki T, Cooper JV, Froehlich JB, Nienaber CA, Eagle KA, International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). *Circulation*. 2007;116:1120–1127.
- 519 Isselbacher EM, Preventza O, Hamilton Black J, Augoustides JG, Beck AW, Bolen 6. 520 MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, 521 DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Schuyler Jones W, Kalahasti 522 V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Gyang Ross E, 523 Schermerhorn ML, Singleton Times S, Tseng EE, Wang GJ, Woo YJ. 2022 524 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A 525 Report of the American Heart Association/American College of Cardiology Joint 526 Committee on Clinical Practice Guidelines. Circulation. 2022;146:e334-e482.
- Mori M, Gan G, Deng Y, Yousef S, Weininger G, Daggula KR, Agarwal R, Shang
   M, Assi R, Geirsson A, Vallabhajosyula P. Development and Validation of a
   Predictive Model to Identify Patients With an Ascending Thoracic Aortic Aneurysm.
   Journal of the American Heart Association. 2021;10:e022102.
- Obel LM, Diederichsen AC, Steffensen FH, Frost L, Lambrechtsen J, Busk M,
   Urbonaviciene G, Egstrup K, Karon M, Rasmussen LM, Gerke O, Bovling AS,
   Lindholt JS. Population-Based Risk Factors for Ascending, Arch, Descending, and
   Abdominal Aortic Dilations for 60-74–Year-Old Individuals. *Journal of the American College of Cardiology*. 2021;78:201–211.
- Pirruccello JP, Lin H, Khurshid S, Nekoui M, Weng L-C, Ramachandran VS,
   Isselbacher EM, Benjamin EJ, Lubitz SA, Lindsay ME, Ellinor PT. Development of
   a Prediction Model for Ascending Aortic Diameter Among Asymptomatic

- 539 Individuals. *JAMA*. 2022;328:1935–1944.
- 540 10. Pirruccello JP, Chaffin MD, Chou EL, Fleming SJ, Lin H, Nekoui M, Khurshid S,
  541 Friedman SF, Bick AG, Arduini A, Weng L-C, Choi SH, Akkad A-D, Batra P, Tucker
  542 NR, Hall AW, Roselli C, Benjamin EJ, Vellarikkal SK, Gupta RM, Stegmann CM,
  543 Juric D, Stone JR, Vasan RS, Ho JE, Hoffmann U, Lubitz SA, Philippakis AA,
  544 Lindsay ME, Ellinor PT. Deep learning enables genetic analysis of the human
  545 thoracic aorta. *Nat Genet*. 2021;
- 546 11. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a
   547 multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD):
   548 The TRIPOD Statement. *Annals of Internal Medicine*. 2015;162:55.
- 549 12. Collins R. UK Biobank Protocol [Internet]. 2007; Available from: 550 https://www.ukbiobank.ac.uk/media/gnkeyh2q/study-rationale.pdf
- Denny JC, Rutter J, Goldstein DB, Philippakis A, Smoller J, Jenkins G, Dishman E.
   The "All of Us" Research Program. New England Journal of Medicine.
   2019;381:668–676.
- 14. Rogers IS, Massaro JM, Truong QA, Mahabadi AA, Kriegel MF, Fox CS,
   Thanassoulis G, Isselbacher EM, Hoffmann U, O'Donnell CJ. Distribution,
   determinants, and normal reference values of thoracic and abdominal aortic
   diameters by computed tomography (from the Framingham Heart Study). *Am J Cardiol.* 2013;111:1510–1516.
- 15. Pirruccello JP, Rämö JT, Choi SH, Chaffin MD, Kany S, Nekoui M, Chou EL,
   Jurgens SJ, Friedman SF, Juric D, Stone JR, Batra P, Ng K, Philippakis AA,
   Lindsay ME, Ellinor PT. The Genetic Determinants of Aortic Distention. *Journal of the American College of Cardiology*. 2023;81:1320–1335.
- 16. Khurshid S, Reeder C, Harrington LX, Singh P, Sarma G, Friedman SF, Di Achille
  P, Diamant N, Cunningham JW, Turner AC, Lau ES, Haimovich JS, Al-Alusi MA,
  Wang X, Klarqvist MDR, Ashburner JM, Diedrich C, Ghadessi M, Mielke J, Eilken
  HM, McElhinney A, Derix A, Atlas SJ, Ellinor PT, Philippakis AA, Anderson CD, Ho
  JE, Batra P, Lubitz SA. Cohort design and natural language processing to reduce
  bias in electronic health records research. NPJ Digit Med. 2022;5:47.
- Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A,
   Benner C, O'Dushlaine C, Barber M, Boutkov B, Habegger L, Ferreira M, Baras A,
   Reid J, Abecasis G, Maxwell E, Marchini J. Computationally efficient whole genome regression for quantitative and binary traits. *Nat Genet*. 2021;53:1097–
   1103.
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P,
   Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A,
   Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for
   identifying the causes of a wide range of complex diseases of middle and old age.
   *PLoS medicine*. 2015;12:e1001779.
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic
   D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean
   G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep
   phenotyping and genomic data. *Nature*. 2018;562:203.
- 583 20. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature Communications*.

- 585 2019;10:1776.
- 586 21. Karlson EW, Boutin NT, Hoffnagle AG, Allen NL. Building the Partners HealthCare
   587 Biobank at Partners Personalized Medicine: Informed Consent, Return of Research
   588 Results, Recruitment Lessons and Operational Considerations. *J Pers Med* 589 [Internet]. 2016 [cited 2020 Jul 14];6. Available from:
   590 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810381/
- 591 22. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, Jain D, Argos M, 592 Arnett DK, Avery C, Barnes KC, Becker LC, Bien SA, Bis JC, Blangero J, 593 Boerwinkle E, Bowden DW, Buyske S, Cai J, Cho MH, Choi SH, Choquet H, 594 Cupples LA, Cushman M, Daya M, Vries PS de, Ellinor PT, Faraday N, Fornage M, 595 Gabriel S, Ganesh S, Graff M, Gupta N, He J, Heckbert SR, Hidalgo B, Hodonsky 596 C, Irvin MR, Johnson AD, Jorgenson E, Kaplan R, Kardia SL, Kelly TN, 597 Kooperberg C, Lasky-Su JA, Loos RJF, Lubitz SA, Mathias RA, McHugh CP, 598 Montgomery C, Moon J-Y, Morrison AC, Palmer ND, Pankratz N, Papanicolaou 599 GJ, Peralta JM, Peyser PA, Rich SS, Rotter JI, Silverman EK, Smith JA, Smith NL, 600 Taylor KD, Thornton TA, Tiwari HK, Tracy RP, Wang T, Weiss ST, Weng LC, 601 Wiggins KL, Wilson JG, Yanek LR, Zöllner S, North KN, Auer PL, Consortium NT-602 O for PM (TOPMed), Hematology & Dopm, Group HW, Raffield LM, Reiner AP, 603 Li Y. Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) 604 Consortium whole genome sequences improves imputation quality and detection of 605 rare variant associations in admixed African and Hispanic/Latino populations. 606 bioRxiv. 2019;683201.
- 607 23. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, 608 Dermitzakis E, Schaffner SF, Yu F, Peltonen L, Dermitzakis E, Bonnen PE, 609 Altshuler DM, Gibbs RA, de Bakker PIW, Deloukas P, Gabriel SB, Gwilliam R, Hunt 610 S, Inouye M, Jia X, Palotie A, Parkin M, Whittaker P, Yu F, Chang K, Hawes A, 611 Lewis LR, Ren Y, Wheeler D, Gibbs RA, Marie Muzny D, Barnes C, Darvishi K, 612 Hurles M, Korn JM, Kristiansson K, Lee C, McCarroll SA, Nemesh J, Dermitzakis 613 E, Keinan A, Montgomery SB, Pollack S, Price AL, Soranzo N, Bonnen PE, Gibbs 614 RA, Gonzaga-Jauregui C, Keinan A, Price AL, Yu F, Anttila V, Brodeur W, Daly MJ, 615 Leslie S, McVean G, Moutsianas L, Nguyen H, Schaffner SF, Zhang Q, Ghori MJR, 616 McGinnis R, McLaren W, Pollack S, Price AL, Schaffner SF, Takeuchi F, 617 Grossman SR, Shlyakhter I, Hostetter EB, Sabeti PC, Adebamowo CA, Foster 618 MW, Gordon DR, Licinio J, Cristina Manca M, Marshall PA, Matsuda I, Ngare D, 619 Ota Wang V, Reddy D, Rotimi CN, Royal CD, Sharp RR, Zeng C, Brooks LD, 620 McEwen JE. The International HapMap 3 Consortium, Principal investigators, 621 Project coordination leaders, Manuscript writing group, Genotyping and QC, 622 ENCODE 3 sequencing and SNP discovery, Copy number variation typing and 623 analysis, Population analysis, Low frequency variation analysis, Linkage 624 disequilibrium and haplotype sharing analysis, et al. Integrating common and rare 625 genetic variation in diverse human populations. Nature. 2010;467:52-58.
- 626 24. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: Using Sequence and Genotype Data to Estimate Haplotypes and Unobserved Genotypes. *Genet Epidemiol.* 2010:34:816–834.
- Venner E, Muzny D, Smith JD, Walker K, Neben CL, Lockwood CM, Empey PE,
   Metcalf GA, Kachulis C, All of Us Research Program Regulatory Working Group,

- Mian S, Musick A, Rehm HL, Harrison S, Gabriel S, Gibbs RA, Nickerson D, Zhou AY, Doheny K, Ozenberger B, Topper SE, Lennon NJ. Whole-genome sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic results as part of the All of Us Research Program. *Genome Med.* 2022;14:34.
- 26. Lim M, Hastie T. Learning Interactions via Hierarchical Group-Lasso
   Regularization. *Journal of Computational and Graphical Statistics*. 2015;24:627–638
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or
   more correlated receiver operating characteristic curves: a nonparametric
   approach. *Biometrics*. 1988;44:837–845.
- 642 28. Pencina MJ, Steyerberg EW, D'Agostino RB. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med.* 2011;30:11–21.
- 645 29. Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E, Sakaue S, Graff M, 646 Eliasen AU, Jiang Y, Raghavan S, Miao J, Arias JD, Mukamel RE, Spracklen CN, 647 Yin X, Chen S-H, Ferreira T, Ji Y, Karedera T, Lull K, Lin K, Malden DE, Medina-648 Gomez C, Machado M, Moore A, Rueger S, Group GC-HW, Team 23andMe 649 Research, Program VMV, Initiative) D (DiscovEHR and MCH, Network) eMERGE 650 (Electronic MR and G, Study LC, Center RG, Consortium TP, Group USS, 651 Chasman DI, Cho YS, Heid IM, McCarthy MI, Ng MCY, O'Donnell CJ, Rivadeneira 652 F, Thorsteinsdottir U, Sun YV, Thai ES, Boehnke M, Deloukas P, Justice AE, 653 Lindgren CM, Loos RJF, Mohlke KL, North KE, Stefansson K, Walters RG, Winkler 654 TW, Young KL, Loh P-R, Yang J, Esko T, Assimes TL, Auton A, Abecasis GR, 655 Willer CJ, Locke AE, Berndt SI, Lettre G, Frayling TM, Okada Y, Wood AR, 656 Visscher PM, Hirschhorn JN. A Saturated Map of Common Genetic Variants Associated with Human Height from 5.4 Million Individuals of Diverse Ancestries 657 658 [Internet]. 2022 [cited 2022 Jan 11]. Available from: 659 https://www.biorxiv.org/content/10.1101/2022.01.07.475305v1
- 660 30. Gurdasani D, Carstensen T, Fatumo S, Chen G, Franklin CS, Prado-Martinez J, Bouman H, Abascal F, Haber M, Tachmazidou I, Mathieson I, Ekoru K, DeGorter 661 662 MK, Nsubuga RN, Finan C, Wheeler E, Chen L, Cooper DN, Schiffels S, Chen Y, 663 Ritchie GRS, Pollard MO, Fortune MD, Mentzer AJ, Garrison E, Bergström A, 664 Hatzikotoulas K, Adeyemo A, Doumatey A, Elding H, Wain LV, Ehret G, Auer PL, 665 Kooperberg CL, Reiner AP, Franceschini N, Maher D, Montgomery SB, Kadie C, 666 Widmer C, Xue Y, Seeley J, Asiki G, Kamali A, Young EH, Pomilla C, Soranzo N, 667 Zeggini E, Pirie F, Morris AP, Heckerman D, Tyler-Smith C, Motala AA, Rotimi C, 668 Kaleebu P, Barroso I, Sandhu MS. Uganda Genome Resource Enables Insights 669 into Population History and Genomic Discovery in Africa. Cell. 2019;179:984-670 1002.e36.

671

# Figure Legends

29/35

# Figure 1: Study cohorts

The sample diagram depicts participant subsets. UK Biobank participants with MRI data were split by random ID into a GWAS group (blue, N=39,524) and a residual group. Individuals in the residual group related within 3 degrees of kinship were removed (N=557), and the residual group was then split into a training group (purple, N=4,896) and an internal validation group (yellow, N=4,962). As depicted in the legend, the GWAS and PRS development was conducted in the GWAS group (blue, N=39,524). Clinical model development was conducted in the GWAS and training groups (blue and purple, N=44,420). The PRS was incorporated into the clinical score using a linear model to produce the AORTA Gene model in the training group (purple, N=4,896). All models were validated in the internal validation set (yellow, N=4,962) and the external validation sets (orange): MGB, FHS, and *All of Us.* MGB: Mass General Brigham Biobank. FHS: Framingham Heart Study. MRI: magnetic resonance imaging. GWAS: genome-wide association study.

# Figure 2: Score calibration curves in the UK Biobank validation set Counterclockwise from top left: AORTA Gene, followed by the clinical AORTA Score, the age and sex model, and the age/sex/genetics model. The x axis represents the predicted ascending aortic diameter; the y axis represents the measured ascending aortic diameter; both are truncated at the same points so that the x and y axes have the same span. Each point represents one of the 4,962 UK Biobank internal validation set participants; orange points represent women while navy points represent men. The blue

**AORTA Gene** 

line shows the smoothed average value, and only extends along the x axis to the limits of the observed data. The black line shows the line of ideal calibration, where a 1 cm greater score would be met by a 1 cm greater aortic diameter. For all plotted scores, the slopes were statistically indistinguishable from one and the intercepts were statistically indistinguishable from zero as detailed in the Results.

#### Figure 3: Variance in a ortic diameter explained by the models

For each cohort, the variance in ascending aortic diameter explained by the model derived from age and sex (navy blue), the clinical model (AORTA Score, slate gray), and the clinical model incorporating the polygenic score (AORTA Gene, orange) is depicted for the internal validation set and the three external validation sets. MGB: Mass General Brigham Biobank. FHS: Framingham Heart Study.

#### Figure 4: Receiver operator characteristic curves

Receiver operator characteristic (ROC) curves for the AORTA Gene model (red) and the clinical AORTA Score model (blue) in the validation cohorts. The dashed diagonal line represents the no-information baseline. Counterclockwise from top left: UK Biobank internal validation, MGB, FHS, and *All of Us.* The AUROC for detecting aortic diameter ≥4cm for the AORTA Gene model in these cohorts was, respectively, 0.834, 0.808, 0.856, and 0.827. The respective AUROC for the clinical AORTA Score was 0.765, 0.767, 0.818, and 0.791. MGB: Mass General Brigham Biobank. FHS: Framingham Heart Study.

# 714 Tables

715

# Table 1: Participant characteristics

	UK Biobank MRI Training		MGB TTE External Validation	FHS CT External Validation	All of Us TTE External Validation	All of Us Aneurysm External Validation
N	44,420	4,962	5,469	1,298	610	164,789
Men	21,053 (47.4%)	2,344 (47.2%)	2,580 (47.2%)	617 (47.5%)	246 (40.3%)	70,861 (43.0%)
Women	23,367 (52.6%)	2,618 (52.8%)	2,889 (52.8%)	681 (52.5%)	364 (59.7%)	93,928 (57.0%)
Age (years)	65.2 (7.7)	65.4 (7.7)	61.1 (14.4)	59.8 (9.0)	66.1 (11.0)	60.3 (10.9)
Medical history						
Hypertension	13,299 (29.9%)	1,501 (30.2%)	4,535 (82.9%)	532 (41.0%)	426 (69.8%)	57,845 (35.1%)
Hyperlipidemia	9,644 (21.7%)	1,103 (22.2%)	942 (17.2%)	257 (19.8%)	155 (25.4%)	6,379 (3.9%)
Diabetes	1,277 (2.9%)	160 (3.2%)	1,750 (32.0%)	115 (8.9%)	210 (34.4%)	25,568 (15.5%)
Heart rate (bpm)	68 (11)	68 (11)	76 (15)	65 (11)	69 (11)	72 (12)
Systolic blood pressure (mmHg)		141 (18)	128 (17)	126 (18)	129 (18)	129 (18)
Diastolic blood pressure (mmHg)		79 (10)	75 (10)	75 (9)	77 (11)	78 (11)
Height (cm)	169 (9)	169 (9)	169 (10)	168 (9)	166 (10)	168 (10)
Weight (kg)	75.2 (14.7)	75.4 (14.9)	84.4 (21.2)	80 (17.3)	88.9 (24.9)	84.5 (21.8)
BMI (kg/m2)	26.3 (4.2)	26.3 (4.3)	29.5 (6.6)	28.3 (5.2)	32.0 (8.4)	30.0 (7.3)
Ascending aortic diameter (cm)	3.18 (0.35)	3.19 (0.35)	3.20 (0.48)	3.45 (0.36)	3.34 (0.45)	NA
Aortic diameter ≥4cm		113 (2.3%)	335 (6.1%)	116 (8.9%)	65 (10.7%)	NA
Prevalent aneurysm		NA	NA	NA	NA	1,904 (1.2%)
Incident aneurysm	NA	NA	NA	NA	NA	1,632 (1.0%)

All values are mean (standard deviation) or count (percent of total). BPM: beats per

717 minute. MGB: Mass General Brigham. BMI: body mass index. MRI: magnetic resonance

718 imaging. CT: computed tomography. TTE: transthoracic echocardiography.

# **Figures**

Figure 1: Study cohorts




Figure 2: Score calibration curves in the UK Biobank validation set




Figure 3: Variance in aortic diameter explained by the models




Figure 4: Receiver operator characteristic curves

